Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.38 |
| ▸ | ESR1 | P03372 | 5/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2412697 | 0.76 | DRD2 (0.34) | KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL2406071 | 0.74 | SMN1; SMN2 (0.45) | KDM4EPOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL2408236 | 0.70 | SMN1; SMN2 (0.34) | KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL2407527 | 0.68 | KDM4E (0.44) | KDM4E | |
| SCHEMBL5380967 | 0.67 | SIGMAR1 (0.44) | KDM4EALDH1A1 | |
| SCHEMBL2408399 | 0.66 | NPC1 (0.41) | KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL2408644 | 0.66 | SCN4A (0.42) | — | |
| SCHEMBL1555898 | 0.65 | NPC1 (0.41) | KDM4EHRH3ALDH1A1 | |
| SCHEMBL1555845 | 0.63 | CYP3A4 (0.42) | POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL12270645 | 0.62 | CHRNB2 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853424-B2 | Protein cross-linking inhibitor | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | BAZ2B, PRMT1, BRIX1 | KDM4E 1022/4885POLB 1280/4885SMN1; SMN2 4119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.